Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein

Journal of Biomedical Science

Volumn 21, Issue 1, 2014, Pages

  Benen, Thomas D ^a,c   Tonks, Paul ^b   Kliche, Alexander ^a   Kapzan, Ruth ^a,d   Heeney, Jonathan L ^b   Wagner, Ralf ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Malvern Instruments GmbH   (Germany)

^d GENEART AG   (Germany)

Author keywords

gp41; HIV 1; Immunization study; Neutralizing antibodies; Vaccine; VLPs

Indexed keywords

DNA; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10E8; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; RECOMBINANT VACCINE; VIRUS LIKE PARTICLE VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CROSS REACTION; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGICAL PROCEDURES; MEMBRANE PROXIMAL EXTERNAL REGION; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PLASMID; PRESERVATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN STABILITY; RABBIT; SERUM; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; GENETICS; HEK293 CELL LINE; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; HEK293 CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; RABBITS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84906924880     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-014-0079-x     Document Type: Article

References (53)

1. A global approach to HIV-1 vaccine development. KE Stephenson, DH Barouch, Immunol Rev 2013 254 295 304 10.1111/imr.12073
2. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? DC Montefiori, JR Mascola, Curr Opin HIV AIDS 2009 4 347 351 10.1097/COH.0b013e32832f4a4d
3. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. AJ Hessell, P Poignard, M Hunter, L Hangartner, DM Tehrani, WK Bleeker, PWHI Parren, PA Marx, DR Burton, Nat Med 2009 15 951 954 10.1038/nm.1974
4. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. ES Gray, MC Madiga, PL Moore, K Mlisana, SS Abdool Karim, JM Binley, GM Shaw, JR Mascola, L Morris, J Virol 2009 83 11265 11274 10.1128/JVI.01359-09
5. HIV entry and its inhibition. DC Chan, PS Kim, Cell 1998 93 681 684 10.1016/S0092-8674(00)81430-0
6. Atomic structure of the ectodomain from HIV-1 gp41. W Weissenhorn, A Dessen, SC Harrison, JJ Skehel, DC Wiley, Nature 1997 387 426 430 10.1038/387426a0
7. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. J Huang, G Ofek, L Laub, MK Louder, NA Doria-Rose, NS Longo, H Imamichi, RT Bailer, B Chakrabarti, SK Sharma, SM Alam, T Wang, Y Yang, B Zhang, SA Migueles, R Wyatt, BF Haynes, PD Kwong, JR Mascola, M Connors, Nature 2012 491 406 412 10.1038/nature11544
8. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. AS Dimitrov, A Jacobs, CM Finnegan, G Stiegler, H Katinger, R Blumenthal, Biochemistry 2007 46 1398 1401 10.1021/bi062245f
9. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. OKJ Sun Z-YJ, M Kim, J Yu, V Brusic, L Song, Z Qiao, J Wang, G Wagner, EL Reinherz, Immunity 2008 28 52 63 10.1016/j.immuni.2007.11.018
10. Broadly Neutralizing Anti-HIV Antibody 4E10 Recognizes a Helical Conformation of a Highly Conserved Fusion-Associated Motif in gp41. R Cardoso, M Zwick, R Stanfield, R Kunert, J Binley, H Katinger, D Burton, I Wilson, Immunity 2005 22 163 173 10.1016/j.immuni.2004.12.011
11. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. SM Alam, M Morelli, SM Dennison, H-X Liao, R Zhang, S-M Xia, S Rits-Volloch, L Sun, SC Harrison, BF Haynes, B Chen, Proc Natl Acad Sci U S A 2009 106 20234 20239 10.1073/pnas.0908713106
12. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. M-Y Zhang, Y Wang, MK Mankowski, RG Ptak, DS Dimitrov, Vaccine 2009 27 857 863 10.1016/j.vaccine.2008.11.083
13. Characterization of a trimeric MPER containing HIV-1 gp41 antigen. A Hinz, G Schoehn, H Quendler, DL Hulsik, G Stiegler, H Katinger, MS Seaman, D Montefiori, W Weissenhorn, Virology 2009 390 221 227 10.1016/j.virol.2009.05.015
14. HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies. J Wang, P Tong, L Lu, L Zhou, L Xu, S Jiang, Y-H Chen, PLoS One 2011 6 18233 10.1371/journal.pone.0018233
15. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. O Lenz, MT Dittmar, A Wagner, B Ferko, K Vorauer-Uhl, G Stiegler, W Weissenhorn, J Biol Chem 2005 280 4095 4101 10.1074/jbc.M411088200
16. A hidden Markov model for predicting transmembrane helices in protein sequences. EL Sonnhammer, G von Heijne, A Krogh, Proc Int Conf Intell Syst Mol Biol 1998 6 175 182
17. Improved prediction of signal peptides: SignalP 3.0. JD Bendtsen, H Nielsen, G von Heijne, S Brunak, J Mol Biol 2004 340 783 795 10.1016/j.jmb.2004.05.028
18. A combined transmembrane topology and signal peptide prediction method. L Käll, A Krogh, ELL Sonnhammer, J Mol Biol 2004 338 1027 1036 10.1016/j.jmb.2004.03.016
19. Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. W Weissenhorn, LJ Calder, A Dessen, T Laue, JJ Skehel, DC Wiley, Proc Natl Acad Sci U S A 1997 94 6065 6069 10.1073/pnas.94.12.6065
20. Comparative protein structure modeling using MODELLER. N Eswar, B Webb, MA Marti-Renom, MS Madhusudhan, D Eramian, M-Y Shen, U Pieper, A Sali, Curr Protoc Protein Sci 2007 Chapter 2 nit 2.9
21. Production, mapping and biological characterisation of monoclonal antibodies to the core protein (p24) of the human immunodeficiency virus type 1. H Wolf, S Modorow, E Soutschek, M Motz, R Grunow, H Döbl, R Von Baehr, AIFO 1990 5 24 29
22. Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6∗ for spatiotemporal regulation of protease activation. C Ludwig, A Leiherer, R Wagner, J Virol 2008 82 4573 4584 10.1128/JVI.02353-07
23. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. L Deml, A Bojak, S Steck, M Graf, J Wild, R Schirmbeck, H Wolf, R Wagner, J Virol 2001 75 10991 11001 10.1128/JVI.75.22.10991-11001.2001
24. Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. M Graf, A Bojak, L Deml, K Bieler, H Wolf, R Wagner, J Virol 2000 74 10822 10826 10.1128/JVI.74.22.10822-10826.2000
25. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. DC Montefiori, Curr Protoc Immunol 2005 Chapter 12 nit 12.11
26. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. GD Tomaras, JM Binley, ES Gray, ET Crooks, K Osawa, PL Moore, N Tumba, T Tong, X Shen, NL Yates, J Decker, CK Wibmer, F Gao, SM Alam, P Easterbrook, S Abdool Karim, G Kamanga, JA Crump, M Cohen, GM Shaw, JR Mascola, BF Haynes, DC Montefiori, L Morris, J Virol 2011 85 11502 11519 10.1128/JVI.05363-11
27. Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface. JD Steckbeck, C Sun, TJ Sturgeon, RC Montelaro, PLoS One 2013 8 65220 10.1371/journal.pone.0065220
28. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. G Frey, J Chen, S Rits-Volloch, MM Freeman, S Zolla-Pazner, B Chen, Nat Struct Mol Biol 2010 17 1486 1491 10.1038/nsmb.1950
29. Incorporation of High Levels of Chimeric Human Immunodeficiency Virus Envelope Glycoproteins into Virus-Like Particles. B-Z Wang, W Liu, S-M Kang, M Alam, C Huang, L Ye, Y Sun, Y Li, DL Kothe, P Pushko, T Dokland, BF Haynes, G Smith, BH Hahn, RW Compans, J Virol 2007 81 10869 10878 10.1128/JVI.00542-07
30. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. R Wagner, L Deml, R Schirmbeck, M Niedrig, J Reimann, H Wolf, Virology 1996 220 128 140 10.1006/viro.1996.0293
31. argeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus. D Kamdem Toukam, M Tenbusch, A Stang, V Temchura, M Storcksdieck Genannt Bonsmann, B Grewe, S Koch, A Meyerhans, G Nchinda, L Kaptue, K Uberla, PLoS One 2012 7 38068 10.1371/journal.pone.0038068
32. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. ET Crooks, PL Moore, M Franti, CS Cayanan, P Zhu, P Jiang, RP de Vries, C Wiley, I Zharkikh, N Schülke, KH Roux, DC Montefiori, DR Burton, JM Binley, Virology 2007 366 245 262 10.1016/j.virol.2007.04.033
33. Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection. NR Derby, Z Kraft, E Kan, ET Crooks, SW Barnett, IK Srivastava, JM Binley, L Stamatatos, J Virol 2006 80 8745 8762 10.1128/JVI.00956-06
34. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. JG Joyce, WM Hurni, MJ Bogusky, VM Garsky, X Liang, MP Citron, RC Danzeisen, MD Miller, JW Shiver, PM Keller, J Biol Chem 2002 277 45811 45820 10.1074/jbc.M205862200
35. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. E Coëffier, J-M Clément, V Cussac, N Khodaei-Boorane, M Jehanno, M Rojas, A Dridi, M Latour, R El Habib, F Barré-Sinoussi, Vaccine 2000 19 684 693 10.1016/S0264-410X(00)00267-X
36. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. M Kim, Z Qiao, J Yu, D Montefiori, EL Reinherz, Vaccine 2007 25 5102 5114 10.1016/j.vaccine.2006.09.071
37. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. M Law, RMF Cardoso, IA Wilson, DR Burton, J Virol 2007 81 4272 4285 10.1128/JVI.02536-06
38. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. M Montero, N Gulzar, K-A Klaric, JE Donald, C Lepik, S Wu, S Tsai, J-P Julien, AJ Hessell, S Wang, S Lu, DR Burton, EF Pai, WF Degrado, JK Scott, J Virol 2012 86 2930 2941 10.1128/JVI.06349-11
39. C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. JD Steckbeck, A-S Kuhlmann, RC Montelaro, J Gen Virol 2013 94 Pt 1 1 19 10.1099/vir.0.046508-0
40. Membrane topology analysis of HIV-1 envelope glycoprotein gp41. S Liu, N Kondo, Y Long, D Xiao, A Iwamoto, Z Matsuda, Retrovirology 2010 7 100 10.1186/1742-4690-7-100
41. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis. NJ Dimmock, Rev Med Virol 2005 15 365 381 10.1002/rmv.476
42. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. SM Cleveland, L McLain, L Cheung, TD Jones, M Hollier, NJ Dimmock, J Gen Virol 2003 84 Pt 3 591 602 10.1099/vir.0.18630-0
43. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. S Beddows, M Franti, AK Dey, M Kirschner, SPN Iyer, DC Fisch, T Ketas, E Yuste, RC Desrosiers, PJ Klasse, PJ Maddon, WC Olson, JP Moore, Virology 2007 360 329 340 10.1016/j.virol.2006.10.032
44. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein. L Ye, Y Sun, J Lin, Z Bu, Q Wu, S Jiang, DA Steinhauer, RW Compans, C Yang, Virology 2006 352 74 85 10.1016/j.virol.2006.04.012
45. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. GR Matyas, L Wieczorek, Z Beck, C Ochsenbauer-Jambor, JC Kappes, NL Michael, VR Polonis, CR Alving, AIDS 2009 23 2069 2077 10.1097/QAD.0b013e32832faea5
46. Elicitation of structure-specific antibodies by epitope scaffolds. G Ofek, FJ Guenaga, WR Schief, J Skinner, D Baker, R Wyatt, PD Kwong, Proc Natl Acad Sci U S A 2010 107 17880 17887 10.1073/pnas.1004728107
47. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. H-X Liao, MC Levesque, A Nagel, A Dixon, R Zhang, E Walter, R Parks, J Whitesides, DJ Marshall, K-K Hwang, J Virol Methods 2009 158 171 179 10.1016/j.jviromet.2009.02.014
48. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. Z Qi, C Pan, H Lu, Y Shui, L Li, X Li, X Xu, S Liu, S Jiang, Biochem Bioph Res Co 2010 398 506 512 10.1016/j.bbrc.2010.06.109
49. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. E Bianchi, JG Joyce, MD Miller, AC Finnefrock, X Liang, M Finotto, P Ingallinella, P McKenna, M Citron, E Ottinger, RW Hepler, R Hrin, D Nahas, C Wu, D Montefiori, JW Shiver, A Pessi, PS Kim, Proc Natl Acad Sci U S A 2010 107 10655 10660 10.1073/pnas.1004261107
50. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. L Ye, Z Wen, K Dong, X Wang, Z Bu, H Zhang, RW Compans, C Yang, PLoS One 2011 6 14813 10.1371/journal.pone.0014813
51. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. Y Zhai, Z Zhong, M Zariffard, GT Spear, L Qiao, Vaccine 2013 31 5422 5429 10.1016/j.vaccine.2013.09.003
52. Comparative mucosal immunogenicity of HIV gp41 membrane-proximal external region (MPER) containing single and multiple repeats of ELDKWA sequence with defensin peptides. T Mohan, P Verma, DN Rao, Immunobiology 2014 219 292 301 10.1016/j.imbio.2013.11.001
53. Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. M Bomsel, D Tudor, A-S Drillet, A Alfsen, Y Ganor, M-G Roger, N Mouz, M Amacker, A Chalifour, L Diomede, G Devillier, Z Cong, Q Wei, H Gao, C Qin, G-B Yang, R Zurbriggen, L Lopalco, S Fleury, Immunity 2011 34 269 280 10.1016/j.immuni.2011.01.015